Blockchain Registration Transaction Record

Kairos Pharma's ENV-105 Combo Triples PFS in Prostate Cancer Trial

Kairos Pharma's ENV-105 plus apalutamide shows 17.7-month PFS in prostate cancer trial, a significant improvement over apalutamide alone. Interim Phase 2 data.

This news matters because it signals a potential breakthrough in treating metastatic castration-resistant prostate cancer, a condition where patients often face limited options and rapid disease progression. The statistically significant PFS benefit—17.7 months versus 2 months—suggests that ENV-105 could meaningfully extend lives and delay the need for more toxic therapies. If validated in later trials, this combination could become a new standard of care, offering hope to thousands of men worldwide. For investors, it highlights Kairos Pharma's innovative approach and could positively impact its stock as the company advances toward pivotal data.